The Members States Perspective

Stavros Malas
Chair – States Representatives Group (SRG)
IMI-Governance

**IMI Joint Undertaking (IMI JU)**
- **Executive Director (+ staff)**
- **Scientific Committee**

**IMI States Representatives Group**

**Stakeholder Forum**

[Diagram showing the relationships between the IMI JU, Governing Board, Executive Director, Scientific Committee, Stakeholder Forum, and IMI States Representatives Group]
States Representatives Group Composition

- EU Member States
- EU Associated/Candidate Countries

Map showing EU member states and EU associated/candidate countries.
States Representatives Group

Mission

• Facilitate the dissemination of information within their own countries

• Provide an opinion on
  – the annual scientific priorities
  – the outcome of the evaluation process
  – the update of the Research Agenda
  – the activities of the IMI-JU
  – the changes to the call and the evaluation process
  – IPR rules
  – the composition of the experts for the SC
States Representatives Group
Perceptions

- 2004-2008
  - Takes 20% of FP7 budget – is it going to work?
  - Pre-competitive research notion – what does it mean?
  - Will all EU academics benefit from IMI funding?
  - Are IP rules conducive to Academia/SME-Pharma collaborations?
  - Is funding model adequate?
States Representatives Group
Realities – Participation to calls 1

- 20% of FP7 – Tremendous Response to first two calls -more response than under FP6

<table>
<thead>
<tr>
<th></th>
<th>CALL 1</th>
<th>CALL 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topics</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>Expressions of Interest</td>
<td>134</td>
<td>124</td>
</tr>
<tr>
<td>Participants</td>
<td>1,294</td>
<td>1,118</td>
</tr>
</tbody>
</table>

- Success rate very low  5-10% for research-intensive projects
States Representatives Group
Realities- Participation to calls 2

Research potential varies across the EU

85 % -12 countries

15 % -27 countries
Why is it an issue?

- FP7
  - 100 € direct costs
  - 60 € direct costs
  - 75% funding-120 €

- IMI
  - 100 € direct costs
  - 20 € direct costs
  - 75% funding-90 €
States Representatives Group
Realities- Overheads 2

- Overhead issue
  - SRG position
    - Change o/h to FP7 rules (should not apply to Pharmas)
  - EFPIA position
    - Change to o/h FP7 rules (should not apply to Pharmas)
  - Commission position
    - Not yet decided
  - GB position
    - TBD July 2010
States Representatives Group

• IPR issues
  – January 2009 GB sets up IPR Working Group
  – February 2009, first recommendations to GB
    • 'Clarifications' issues
      – Issues which need to be further explained or elaborated, but do not require change in the fundamental principles underlying the written policy.

• 'Policy issues'
  – Issues that do impact the substance and fundamental principles underlying the written policy and where additional explanations would not suffice to address the concerns. Possible action followed: amendments of the articles

• Further discussion on Policy issues – Ongoing
• Concluding remarks
  – Strong enthusiasm so far for stage 1 submissions, is it going to continue (low success rate)?
  – SRG expects to have o/h and IPR issues resolved before the third call.
  – Will IMI have a structuring effect on European Research Area?
  – Will notions for P-P collaborations change?
  – FP8?